Progesterone-Inducible Cytokeratin 5-Positive Cells in Luminal Breast Cancer Exhibit Progenitor Properties

Hormones and Cancer

Volumn 4, Issue 1, 2013, Pages 36-49

  Axlund, Sunshine Daddario ^a   Yoo, Byong Hoon ^a   Rosen, Rachel B ^a   Schaack, Jerome ^a   Kabos, Peter ^b   LaBarbera, Daniel V ^a   Sartorius, Carol A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; ESTROGEN RECEPTOR; GESTAGEN; GREEN FLUORESCENT PROTEIN; LUCIFERASE; MESSENGER RNA; PROGESTERONE; PROGESTERONE RECEPTOR; STEROID HORMONE; VIRUS VECTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL ISOLATION; CELL POPULATION; CELL SELECTION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROGESTIN IMPLANT; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEM CELL EXPANSION;

EID: 84872348736     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-012-0127-5     Document Type: Article

References (63)

1. Beral V, Reeves G, Bull D, Green J (2011) Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103(4): 296-305.
2. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304(15): 1684-1692.
3. Horwitz KB, Sartorius CA (2008) Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 93(9): 3295-3298.
4. Axlund SD, Sartorius CA (2012) Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol 357(1-2): 71-79.
5. Huggins C, Moon RC, Morii S (1962) Extinction of experimental mammary cancer. I. Estradiol-17beta and progesterone. Proc Natl Acad Sci U S A 48: 379-386.
6. Aldaz CM, Liao QY, LaBate M, Johnston DA (1996) Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 17(9): 2069-2072.
7. Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW (1999) Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res 59(17): 4276-4284.
8. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER et al (2010) Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299): 798-802.
9. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL et al (2010) Progesterone induces adult mammary stem cell expansion. Nature 465(7299): 803-807.
10. Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI et al (2009) DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150(7): 3318-3326.
11. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA (2008) Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A 105(15): 5774-5779.
12. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R et al (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320): 103-107.
13. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320): 98-102.
14. Obr AE, Edwards DP (2012) The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 357(1-2): 4-17.
15. Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A et al (2011) Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat 128(1): 45-55.
16. Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, et al (2012) Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene. doi: 10. 1038/onc. 2012. 275.
17. Gusterson B (2009) Do 'basal-like' breast cancers really exist? Nat Rev Cancer 9(2): 128-134.
18. Gusterson BA, Ross DT, Heath VJ, Stein T (2005) Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7(4): 143-148.
19. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15(8): 907-913.
20. Boecker W, Moll R, Poremba C, Holland R, van Diest PJ, Dervan P et al (2002) Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 82(6): 737-746.
21. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797): 747-752.
22. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF et al (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203(2): 661-671.
23. Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW et al (2012) Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A 109(8): 2742-2747.
24. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100(7): 3983-3988.
25. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al (2007) ALDH1 Is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5): 555-567.
26. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P et al (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69(4): 1302-1313.
27. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K et al (2008) The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10(3): R53.
28. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP (2007) The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 21(2): 359-375.
29. Pink JJ, Bilimoria MM, Assikis J, Jordan VC (1996) Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer 74(8): 1227-1236.
30. Byrne C, Fuchs E (1993) Probing keratinocyte and differentiation specificity of the human K5 promoter in vitro and in transgenic mice. Mol Cell Biol 13(6): 3176-3190.
31. Gordon DF, Woodmansee WW, Lewis SR, James RA, Wood WM, Ridgway EC (1999) Cloning of the mouse somatostatin receptor subtype 5 gene: promoter structure and function. Endocrinology 140(12): 5598-5608.
32. Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA, et al (2012) A High-Content Assay to Identify Small-Molecule Modulators of a Cancer Stem Cell Population in Luminal Breast Cancer. J Biomol Screen 17(9): 1211-1220.
33. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6): 1101-1108.
34. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J et al (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3): 259-273.
35. Shen T, Horwitz KB, Lange CA (2001) Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol 21(18): 6122-6131.
36. Cowan RA, Cowan SK, Grant JK (1977) Binding of methyltrienolone (R1881) to a progesterone receptor-like component of human prostatic cytosol. J Endocrinol 74(2): 281-289.
37. Nordeen SK, Kuhnel B, Lawler-Heavner J, Barber DA, Edwards DP (1989) A quantitative comparison of dual control of a hormone response element by progestins and glucocorticoids in the same cell line. Mol Endocrinol 3(8): 1270-1278.
38. Ariazi EA, Leitao A, Oprea TI, Chen B, Louis T, Bertucci AM et al (2007) Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther 6(11): 2817-2827.
39. Li X, Wong J, Tsai SY, Tsai MJ, O'Malley BW (2003) Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol 23(11): 3763-3773.
40. Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17(3): 313-319.
41. Musgrove EA, Lee CS, Sutherland RL (1991) Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11(10): 5032-5043.
42. Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA et al (2010) Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 15(2): 235-252.
43. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17(10): 1253-1270.
44. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5): 1368-1376.
45. Boecker W, Buerger H (2003) Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif 36(Suppl 1): 73-84.
46. Tran CP, Lin C, Yamashiro J, Reiter RE (2002) Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 1(2): 113-121.
47. Uzgare AR, Xu Y, Isaacs JT (2004) In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 91(1): 196-205.
48. Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L, Gudjonsson T, Rank F, LaBarge MA et al (2007) Evidence for a stem cell hierarchy in the adult human breast. J Cell Biol 177(1): 87-101.
49. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO et al (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 108(19): 7950-7955.
50. Iliopoulos D, Hirsch HA, Wang G, Struhl K (2011) Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 108(4): 1397-1402.
51. Kim RS, Avivar-Valderas A, Estrada Y, Bragado P, Sosa MS, Aguirre-Ghiso JA et al (2012) Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS One 7(4): e35569.
52. Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, et al (2012) A refined molecular taxonomy of breast cancer. Oncogene 31: 1196-1206.
53. Fillmore CM, Gupta PB, Rudnick JA, Caballero S, Keller PJ, Lander ES et al (2010) Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci U S A 107(50): 21737-21742.
54. Clarke CL, Graham J, Roman SD, Sutherland RL (1991) Direct transcriptional regulation of the progesterone receptor by retinoic acid diminishes progestin responsiveness in the breast cancer cell line T-47D. J Biol Chem 266(28): 18969-18975.
55. Roman SD, Clarke CL, Hall RE, Alexander IE, Sutherland RL (1992) Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res 52(8): 2236-2242.
56. Gudas LJ, Wagner JA (2011) Retinoids regulate stem cell differentiation. J Cell Physiol 226(2): 322-330.
57. Tulachan SS, Doi R, Kawaguchi Y, Tsuji S, Nakajima S, Masui T et al (2003) All-trans retinoic acid induces differentiation of ducts and endocrine cells by mesenchymal/epithelial interactions in embryonic pancreas. Diabetes 52(1): 76-84.
58. Baldassarre G, Boccia A, Bruni P, Sandomenico C, Barone MV, Pepe S et al (2000) Retinoic acid induces neuronal differentiation of embryonal carcinoma cells by reducing proteasome-dependent proteolysis of the cyclin-dependent inhibitor p27. Cell Growth Differ 11(10): 517-526.
59. Tang XH, Gudas LJ (2011) Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 6: 345-364.
60. Koay DC, Zerillo C, Narayan M, Harris LN, DiGiovanna MP (2010) Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations. Breast Cancer Res 12(4): R62.
61. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A (2006) Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer 13(1): 51-68.
62. Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, et al (2012) Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen dependent gene signatures. Breast Cancer Res Treat 135(2): 415-432.
63. Santen RJ, Yue W, Heitjan DF (2012) Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomark Prev 21(7): 1038-1048.